MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J15
25 active Medicare policies list 81517, and 3 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15
J5
J8
J15 · Effective Aug 10, 2026
JE · Effective Aug 10, 2026
JF · Effective Aug 10, 2026
JJ · Effective Aug 10, 2026
3 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of 81517 |
|---|---|---|
| Noninvasive Tests for Hepatic Fibrosis | Feb 20, 2024 | Covered |
| Policy | Effective | Status of 81517 |
|---|---|---|
| Concert Genetic Testing: Gastroenterology | Not recorded | Referenced |
| Policy | Effective | Status of 81517 |
|---|---|---|
| Algorithmic Tests for Liver Fibrosis | Oct 1, 2026 | Not covered |
JM · Effective Aug 10, 2026
J5 · Effective Aug 10, 2026
J8 · Effective Aug 10, 2026
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
J5 · Effective Jul 1, 2026